Free Trial

Lineage Cell Therapeutics (LCTX) Short Interest Ratio & Short Volume

$1.00
+0.01 (+1.01%)
(As of 05/31/2024 ET)

Lineage Cell Therapeutics Short Interest Data

Current Short Interest
12,370,000 shares
Previous Short Interest
10,900,000 shares
Change Vs. Previous Month
+13.49%
Dollar Volume Sold Short
$0.00
Short Interest Ratio
12.2 Days to Cover
Last Record Date
May 15, 2024
Outstanding Shares
188,800,000 shares
Percentage of Shares Shorted
6.55%
Today's Trading Volume
516,151 shares
Average Trading Volume
1,309,611 shares
Today's Volume Vs. Average
39%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Lineage Cell Therapeutics ?

Sign up to receive the latest short interest report for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

LCTX Short Interest Over Time

LCTX Days to Cover Over Time

LCTX Percentage of Float Shorted Over Time

Lineage Cell Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
5/15/202412,370,000 shares $0.00 +13.5%N/A12.2 $0.00
4/30/202410,900,000 shares $0.00 +3.0%N/A11 $0.00
4/15/202410,580,000 shares $0.00 +1.7%N/A11.2 $0.00
3/31/202410,400,000 shares $0.00 +4.2%N/A11.4 $0.00
3/15/20249,980,000 shares $0.00 +3.7%N/A11.9 $0.00
2/29/20249,620,000 shares $0.00 -4.2%N/A11.5 $0.00
2/15/202410,040,000 shares $0.00 +18.7%N/A13.1 $0.00
1/31/20248,460,000 shares $0.00 +7.4%N/A11.3 $0.00
1/15/20247,880,000 shares $0.00 +13.5%N/A12.7 $0.00
12/31/20236,940,000 shares $0.00 +12.9%N/A11.3 $0.00
12/15/20236,150,000 shares $0.00 -3.5%N/A11.9 $0.00
11/30/20236,370,000 shares $0.00 +6.0%N/A13.4 $0.00
11/15/20236,010,000 shares $0.00 -2.3%N/A13.3 $0.00
10/31/20236,150,000 shares $7.01 million -2.5%N/A14.1 $1.14
10/15/20236,310,000 shares $0.00 +1.5%N/A14.2 $0.00
9/30/20236,220,000 shares $0.00 No ChangeN/A13.2 $0.00
9/15/20236,220,000 shares $0.00 +0.7%N/A13.3 $0.00
8/31/20236,180,000 shares $0.00 +1.0%N/A8.1 $0.00
8/15/20236,120,000 shares $0.00 -0.3%N/A7.8 $0.00
7/31/20236,140,000 shares $0.00 -3.6%N/A8.1 $0.00
7/15/20236,370,000 shares $0.00 -1.1%N/A8.6 $0.00
6/30/20236,440,000 shares $0.00 +19.0%N/A9 $0.00
6/15/20235,410,000 shares $0.00 +13.7%N/A7.7 $0.00
5/31/20234,760,000 shares $0.00 +11.5%N/A12.7 $0.00
5/15/20234,270,000 shares $0.00 -6.0%N/A12.8 $0.00
4/30/20234,540,000 shares $0.00 -0.2%N/A12.9 $0.00
4/15/20234,550,000 shares $0.00 +2.9%N/A13 $0.00
3/31/20234,420,000 shares $0.00 +7.3%N/A12.9 $0.00
3/15/20234,120,000 shares $0.00 -1.2%N/A10.9 $0.00
2/28/20234,170,000 shares $0.00 -0.5%N/A11.2 $0.00
2/15/20234,190,000 shares $0.00 +1.0%N/A11.3 $0.00
1/31/20234,150,000 shares $0.00 -0.2%N/A10.5 $0.00
1/15/20234,160,000 shares $0.00 +2.0%N/A10.9 $0.00
12/30/20224,080,000 shares $0.00 -4.0%N/A10.5 $0.00
12/15/20224,250,000 shares $0.00 -1.6%N/A12.5 $0.00
11/30/20224,320,000 shares $0.00 +0.7%N/A13.4 $0.00
11/15/20224,290,000 shares $0.00 -0.2%N/A13.8 $0.00
10/31/20224,300,000 shares $0.00 -3.4%N/A15 $0.00
10/15/20224,450,000 shares $0.00 -0.5%N/A13.9 $0.00
9/30/20224,470,000 shares $0.00 +0.7%N/A14.2 $0.00
The Only Energy Play You Should Be Looking At (Ad)

Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.

Click here to get all the information about it.
9/15/20224,440,000 shares $0.00 -2.8%N/A6.6 $0.00
8/31/20224,570,000 shares $0.00 +2.0%N/A6 $0.00
8/15/20224,480,000 shares $0.00 -7.4%N/A5.3 $0.00
7/31/20224,840,000 shares $0.00 -2.6%N/A5.3 $0.00
7/15/20224,970,000 shares $0.00 -9.3%N/A5.3 $0.00
6/30/20225,480,000 shares $0.00 -38.6%N/A5.4 $0.00
6/15/20228,930,000 shares $0.00 -7.8%N/A8.9 $0.00
5/31/20229,690,000 shares $0.00 -8.3%N/A14 $0.00
5/15/202210,570,000 shares $0.00 +5.0%N/A15.7 $0.00
4/30/202210,070,000 shares $0.00 +12.5%N/A15.7 $0.00
4/15/20228,950,000 shares $0.00 -3.8%N/A13.3 $0.00
3/31/20229,300,000 shares $0.00 +1.8%N/A13 $0.00
3/15/20229,140,000 shares $0.00 +5.2%N/A10.3 $0.00
2/28/20228,690,000 shares $0.00 -3.3%N/A7.6 $0.00
2/15/20228,990,000 shares $0.00 +4.9%N/A7.3 $0.00
1/31/20228,570,000 shares $13.54 million +0.2%N/A6.9 $1.58
1/15/20228,550,000 shares $0.00 +7.7%N/A6.9 $0.00
12/31/20217,940,000 shares $0.00 -23.3%N/A7.1 $0.00
12/15/202110,350,000 shares $0.00 +23.7%N/A9.8 $0.00
11/30/20218,370,000 shares $18.92 million +9.3%N/A10.5 $2.26
11/15/20217,660,000 shares $0.00 -6.6%N/A10.8 $0.00
10/29/20218,200,000 shares $18.70 million No ChangeN/A12.1 $2.28
10/15/20218,200,000 shares $0.00 -6.8%N/A12.6 $0.00
9/30/20218,800,000 shares $0.00 +14.3%N/A12.4 $0.00
9/15/20217,700,000 shares $0.00 +1.1%N/A7.4 $0.00
8/31/20217,620,000 shares $0.00 -6.6%N/A7.2 $0.00
8/13/20218,160,000 shares $0.00 -8.0%N/A6.6 $0.00
7/30/20218,870,000 shares $0.00 -2.0%N/A6.8 $0.00
7/15/20219,050,000 shares $0.00 +6.2%5.6%6.4 $0.00
6/30/20218,520,000 shares $0.00 +37.2%5.3%6 $0.00
6/15/20216,210,000 shares $0.00 -3.1%3.9%5.4 $0.00
5/28/20216,410,000 shares $0.00 +2.7%4.0%5.4 $0.00
5/14/20216,240,000 shares $0.00 +13.0%N/A5.2 $0.00
4/30/20215,520,000 shares $0.00 +1.7%N/A3.7 $0.00
4/15/20215,430,000 shares $13.68 million +1.9%N/A3.5 $2.52
3/31/20215,330,000 shares $13.86 million +25.4%N/A2.9 $2.60
3/15/20214,250,000 shares $10.24 million +10.4%N/A2.2 $2.41
2/26/20213,850,000 shares $9.09 million -14.6%2.6%2 $2.36
2/12/20214,510,000 shares $10.19 million -2.0%3.0%2.6 $2.26
1/29/20214,600,000 shares $11.27 million -23.1%3.1%2.9 $2.45
1/15/20215,980,000 shares $17.46 million +7.4%4.0%4.2 $2.92
12/31/20205,570,000 shares $9.69 million -10.7%3.7%4.9 $1.74
12/15/20206,240,000 shares $11.42 million -12.9%4.2%6.1 $1.83
11/30/20207,160,000 shares $10.02 million +1.0%4.8%8.2 $1.40
11/15/20207,090,000 shares $10.42 million -10.8%4.8%8.7 $1.47
10/30/20207,950,000 shares $9.22 million -2.6%5.3%10.6 $1.16
10/15/20208,160,000 shares $11.18 million +12.4%5.5%10.7 $1.37
9/30/20207,260,000 shares $6.80 million +28.0%4.9%10.2 $0.94
9/15/20205,670,000 shares $5.33 million -9.1%3.8%5.9 $0.94
8/31/20206,240,000 shares $5.71 million +7.8%4.2%6.1 $0.92
The Only Energy Play You Should Be Looking At (Ad)

Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.

Click here to get all the information about it.
8/14/20205,790,000 shares $5.33 million -3.8%3.9%4.5 $0.92
7/31/20206,020,000 shares $4.94 million +11.3%4.0%4.7 $0.82
7/15/20205,410,000 shares $4.04 million -1.3%3.6%4.1 $0.75
6/30/20205,480,000 shares $5.04 million -29.5%3.7%4.3 $0.92
6/15/20207,770,000 shares $7.76 million +7.9%5.2%7.8 $1.00
5/29/20207,200,000 shares $6.35 million -17.9%4.8%7.9 $0.88
5/15/20208,770,000 shares $7.53 million +12.9%5.9%10.9 $0.86
4/30/20207,770,000 shares $6.60 million +3.2%5.2%10 $0.85
4/15/20207,530,000 shares $5.75 million +3.0%5.1%8.2 $0.76
3/31/20207,310,000 shares $5.70 million +1.0%4.9%7.8 $0.78
3/13/20207,234,900 shares $5.57 million +12.2%5.1%6.2 $0.77
2/28/20206,450,000 shares $4.90 million +2.2%4.4%5.6 $0.76
2/14/20206,310,000 shares $5.49 million -3.5%4.3%5.8 $0.87
1/31/20206,540,000 shares $7.39 million +7.0%4.4%6.5 $1.13
1/15/20206,110,000 shares $9.71 million -1.0%4.1%7.4 $1.59
12/31/20196,170,000 shares $6.42 million -0.8%4.2%9 $1.04

LCTX Short Interest - Frequently Asked Questions

What is Lineage Cell Therapeutics' current short interest?

Short interest is the volume of Lineage Cell Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 12,370,000 shares of LCTX short. Learn More on Lineage Cell Therapeutics' current short interest.

What is a good short interest ratio for Lineage Cell Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LCTX shares currently have a short interest ratio of 12.0. Learn More on Lineage Cell Therapeutics's short interest ratio.

Is Lineage Cell Therapeutics' short interest increasing or decreasing?

Lineage Cell Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 12,370,000 shares, an increase of 13.5% from the previous total of 10,900,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Lineage Cell Therapeutics' short interest compare to its competitors?

Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Lineage Cell Therapeutics: REGENXBIO Inc. (8.14%), CARGO Therapeutics, Inc. (13.82%), HilleVax, Inc. (2.98%), iTeos Therapeutics, Inc. (7.82%), Taysha Gene Therapies, Inc. (9.11%), Valneva SE (0.10%), Exscientia plc (3.66%), Adaptive Biotechnologies Co. (8.92%), Cabaletta Bio, Inc. (18.85%), Alector, Inc. (10.33%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

What does it mean to sell short Lineage Cell Therapeutics stock?

Short selling LCTX is an investing strategy that aims to generate trading profit from Lineage Cell Therapeutics as its price is falling. LCTX shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Lineage Cell Therapeutics?

A short squeeze for Lineage Cell Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of LCTX, which in turn drives the price of the stock up even further.

How often is Lineage Cell Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LCTX, twice per month. The most recent reporting period available is May, 15 2024.



More Short Interest Resources from MarketBeat

This page (NYSEAMERICAN:LCTX) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners